Opportunity Information: Apply for PAR 14 185
Apply for PAR 14 185
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Enabling Resources for Pharmacogenomics (R24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.859 Biomedical Research and Research Training.
- This funding opportunity was created on Apr 22, 2014 and posted on Apr 22, 2014.
- Applicants must submit their applications by Sep 25, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: City or township governments State governments Private institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts County governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
PAR-14-185, titled "Enabling Resources for Pharmacogenomics (R24)," is a National Institutes of Health (NIH) discretionary grant opportunity in the health and biomedical research area (CFDA 93.859) that was designed to fund practical, field-wide resources that make pharmacogenomics research and its real-world use move faster. The central idea is not to fund a single investigator's hypothesis-driven project, but to support a shared resource that the broader pharmacogenomics community can use, where the deliverable is something tangible and enabling: a platform, dataset, tool, service, standard, infrastructure component, or other organized capability that lowers barriers, improves quality, and accelerates discovery and/or implementation.
A key requirement is that the proposed resource must respond to an established, clearly demonstrated community need and must benefit the field broadly rather than serving only a narrow group. The FOA emphasizes that the activities should be sharply defined and realistically scoped, with a design that is clearly optimized to achieve its purpose. In practice, that means reviewers are looking for proposals with a concrete plan, well-justified methods and operational choices, and a clear explanation of why this resource (and not something else) is the right solution for an identified bottleneck in pharmacogenomics.
The announcement also stresses strong project management and accountability. Applicants are expected to build evaluation measures into the resource from the start, so that progress and impact can be assessed rather than simply described. This includes defining success metrics, tracking adoption and usage by the community, monitoring performance and quality, and documenting outcomes in a way that makes the resource's value demonstrable. Alongside evaluation, the FOA calls for staffing that is "judicious," meaning the team should be appropriately sized and composed for the work (for example, combining scientific leadership with engineering, data management, user support, and governance capabilities as needed) without being inflated.
Partnerships are highlighted as important where appropriate, reflecting the reality that many enabling resources in pharmacogenomics rely on coordination across institutions, consortia, clinical sites, professional societies, or other stakeholders. The FOA also signals a preference for resources that have either a proven track record or a convincing rationale for why the team is well positioned to deliver, and it notes that an ideal resource has a finite lifetime. That point generally implies the resource should have a clear lifecycle plan: development and deployment, maturation and broad use, and either a transition plan for sustainability or a defined endpoint once objectives are achieved, rather than an open-ended commitment without an exit strategy.
Impact is the bottom line. NIH frames the expected outcome as "highly impactful in a demonstrable way," which implies that the resource should meaningfully change what the community can do by improving speed, reliability, scale, interoperability, or implementation readiness in pharmacogenomics. The FOA is explicitly aimed at resources that accelerate new research discoveries and/or help translate discoveries into practice, which in pharmacogenomics often includes the movement of genomic and drug-response knowledge into clinical decision support, standards, guidelines, or validated workflows that can be implemented in health systems.
The opportunity strongly encourages advance consultation with NIH scientific/research staff before applying, specifically to confirm that the proposed resource concept fits the scope and intent of the FOA. That guidance is important because R24 resource applications can vary widely, and early discussion can help ensure the proposal is framed around community-wide enabling value rather than drifting into a standard research project.
From an administrative standpoint, PAR-14-185 was posted and created on April 22, 2014, with an original and current closing date listed as September 25, 2016, and it was archived on October 26, 2016. Cost sharing or matching was not required. Eligibility was broad across U.S.-based organizations and governmental units, including state and local governments, tribal governments and tribal organizations, public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), public housing authorities/Indian housing authorities, small businesses, and for-profit organizations other than small businesses, along with various mission-serving institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, TCCUs, and Alaska Native and Native Hawaiian-serving institutions. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations were not eligible to apply, though foreign components as defined by the NIH Grants Policy Statement were allowed, reflecting NIH's usual approach to limited but permissible international involvement when it strengthens the project.
For applicants seeking the full official details, NIH provided the announcement on its grants guide site (linked in the record), and the NIH Office of Extramural Research (OER) webmaster contact was listed for access or linking issues.
Frequently Asked Questions (FAQs): PAR-14-185 - Enabling Resources for Pharmacogenomics (R24)
What is PAR-14-185?
PAR-14-185 is a National Institutes of Health (NIH) discretionary funding opportunity titled "Enabling Resources for Pharmacogenomics (R24)." It falls within health and biomedical research and is associated with CFDA 93.859.
What is the main purpose of this funding opportunity?
The purpose is to support practical, field-wide enabling resources that speed up pharmacogenomics research and its real-world use. The focus is on creating something the broader pharmacogenomics community can use to lower barriers, improve quality, and accelerate discovery and/or implementation.
What kinds of deliverables does NIH expect under this R24 resource program?
The FOA emphasizes tangible, enabling deliverables such as a platform, dataset, tool, service, standard, infrastructure component, or another organized capability that the field can use broadly.
Is this meant to fund a traditional hypothesis-driven research project?
No. The central idea is not to fund a single investigator's hypothesis-driven project. Instead, it supports a shared resource intended to enable the broader community rather than answering one lab's specific research question.
Who is the intended beneficiary of the proposed resource?
The proposed resource is expected to benefit the pharmacogenomics field broadly. A key requirement is that it must address an established, clearly demonstrated community need and not primarily serve only a narrow group.
What does it mean that the resource must respond to a "clearly demonstrated community need"?
It means the proposal should be anchored in an established need in the pharmacogenomics community. The FOA expects applicants to show that the resource addresses a real bottleneck or barrier recognized by the field, and that the proposed solution is appropriate for that need.
How should applicants think about scope and design for this opportunity?
The FOA stresses that activities should be sharply defined and realistically scoped, with a design optimized to achieve the resource's purpose. Reviewers are looking for a concrete plan, well-justified methods and operational choices, and a clear rationale for why the proposed resource is the right solution to the identified bottleneck.
What level of project management and accountability is expected?
Strong project management and accountability are emphasized. The FOA expects applicants to build evaluation measures into the resource from the start so progress and impact can be assessed in measurable ways rather than described in general terms.
What types of evaluation measures are expected?
Examples called for in the FOA include defining success metrics, tracking adoption and usage by the community, monitoring performance and quality, and documenting outcomes so the resource's value is demonstrable.
What does NIH mean by "judicious" staffing?
It means the team should be appropriately sized and composed for the work, without being inflated. Depending on the resource, this could involve a mix of scientific leadership and roles such as engineering, data management, user support, and governance.
Are partnerships encouraged for PAR-14-185?
Yes. Partnerships are highlighted as important where appropriate, reflecting that many enabling resources in pharmacogenomics require coordination across institutions, consortia, clinical sites, professional societies, or other stakeholders.
Does NIH prefer applicants with prior experience delivering similar resources?
The FOA signals a preference for resources with either a proven track record or a convincing rationale for why the team is well positioned to deliver.
What does it mean that an ideal resource has a "finite lifetime"?
It implies the resource should have a clear lifecycle plan: development and deployment, maturation and broad use, and either a transition plan for sustainability or a defined endpoint once objectives are achieved. The FOA discourages an open-ended commitment without an exit strategy.
What kind of impact is NIH looking for?
NIH frames the expected outcome as "highly impactful in a demonstrable way." The resource should meaningfully change what the community can do by improving speed, reliability, scale, interoperability, and/or implementation readiness in pharmacogenomics.
Does the FOA support resources that help translate pharmacogenomics into clinical practice?
Yes. The FOA explicitly aims at resources that accelerate new research discoveries and/or help translate discoveries into practice. In pharmacogenomics, that can include supporting movement of genomic and drug-response knowledge into clinical decision support, standards, guidelines, or validated workflows that can be implemented in health systems.
Is advance consultation with NIH staff recommended?
Yes. The opportunity strongly encourages advance consultation with NIH scientific/research staff before applying to confirm the proposed resource concept fits the scope and intent of the FOA.
Why is early discussion with NIH staff particularly important for an R24 resource application?
Because R24 resource applications can vary widely. Early discussion can help ensure the proposal stays centered on community-wide enabling value and does not drift into a standard research project that is outside the FOA's intent.
When was PAR-14-185 posted, and what is its status now?
The announcement was posted and created on April 22, 2014. The original and current closing date listed was September 25, 2016. It was archived on October 26, 2016.
Was cost sharing or matching required?
No. Cost sharing or matching was not required.
What types of organizations were eligible to apply?
Eligibility was broad across U.S.-based organizations and governmental units, including state and local governments, tribal governments and tribal organizations, public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), public housing authorities/Indian housing authorities, small businesses, and for-profit organizations other than small businesses. The FOA also included various mission-serving institutions such as HBCUs, Hispanic-serving institutions, AANAPISIs, TCCUs, and Alaska Native and Native Hawaiian-serving institutions.
Are non-U.S. (foreign) institutions eligible to apply directly?
No. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations were not eligible to apply.
Are any forms of international involvement allowed?
Yes. Foreign components, as defined by the NIH Grants Policy Statement, were allowed. This reflects NIH's common approach of permitting limited international involvement when it strengthens the project, even though foreign institutions cannot apply directly under this opportunity.
Where can applicants find the official funding announcement details?
NIH provided the announcement on its grants guide site (linked in the record for the opportunity). For access or linking issues, the NIH Office of Extramural Research (OER) webmaster contact was listed.
Browse more opportunities from the same category: Health
Next opportunity: Targeting Co dependent Molecular Pathways in Oral Cancer (U01)
Previous opportunity: 2014 Hazardous Fuels Wood to Energy Grant Program Request for Proposals
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 185
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 185) also looked into and applied for these:
| Funding Opportunity |
|---|
| Targeting Co dependent Molecular Pathways in Oral Cancer (U01) Apply for RFA DE 15 004 Funding Number: RFA DE 15 004 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Promoting Innovation in Emergency Medical Services Apply for DTNH22 14 R 00029 Funding Number: DTNH22 14 R 00029 Agency: DOT/National Highway Traffic Safety Administration Category: Health Funding Amount: $225,000 |
| Agricultural, Forestry and Fishing Safety and Health Research Apply for PAR 14 175 Funding Number: PAR 14 175 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $275,000 |
| Cooperative Agreement for Workforce Development in Vietnam HIV Addiction Technology Transfer Center (Short Title Vietnam H ATTC) Apply for TI 14 012 Funding Number: TI 14 012 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $350,000 |
| Revision Applications for NIDCR funded Cooperative Agreements (U01) Apply for PAR 14 187 Funding Number: PAR 14 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Audacious Goal Initiative Addressing Technical Needs and Opportunities for Imaging the Visual System (U01) Apply for RFA EY 14 001 Funding Number: RFA EY 14 001 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Native Hawaiian Health Care Improvement Act Apply for HRSA 14 096 Funding Number: HRSA 14 096 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving the Capacity of Panel Physicians Performing Overseas Medical Examinations of U.S. Bound Immigrants and Refugees Apply for CDC RFA CK14 1403 Funding Number: CDC RFA CK14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Genomic Resource Grants for Community Resource Projects (U41) Apply for PAR 14 191 Funding Number: PAR 14 191 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alliance for Innovation on Maternal HealthImproving Maternal Health and Safety Apply for HRSA 14 134 Funding Number: HRSA 14 134 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Limited Competition Centers of Biomedical Research Excellence (COBRE) Phase III Transitional Centers (P30) Apply for PAR 14 178 Funding Number: PAR 14 178 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 14 192 Funding Number: PAR 14 192 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Epidemiology and Prevention in Alcohol Research (R21) Apply for PA 14 188 Funding Number: PA 14 188 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epidemiology and Prevention in Alcohol Research (R03) Apply for PA 14 189 Funding Number: PA 14 189 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Epidemiology and Prevention in Alcohol Research (R01) Apply for PA 14 190 Funding Number: PA 14 190 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Agreements for Tribal Behavioral Health Apply for SM 14 013 Funding Number: SM 14 013 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $200,000 |
| Emerging Pandemic Threats Program 2, PREDICT 2 Apply for RFA OAA 14 000019 Funding Number: RFA OAA 14 000019 Agency: Agency for International Development Category: Health Funding Amount: $100,000,000 |
| Sickle Cell Disease Treatment Demonstration Program Regional Collaborative Apply for HRSA 14 078 Funding Number: HRSA 14 078 Agency: Health Resources and Services Administration Category: Health Funding Amount: $850,000 |
| Immunization Information Systems (IIS) Capacity Building Apply for CDC RFA IP12 120103CONT14 Funding Number: CDC RFA IP12 120103CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Partner and Implement Public Health Strategies Related to Apply for CDC RFA DP10 100305CONT14 Funding Number: CDC RFA DP10 100305CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 185", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.